NASDAQ:JNP Juniper Pharmaceuticals (JNP) Stock Price, News & Analysis → Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad) Free JNP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$11.45▼$11.5050-Day Range N/A52-Week Range$4.30▼$13.25Volume28,513 shsAverage Volume155,873 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Juniper Pharmaceuticals alerts: Email Address Ad Paradigm PressCould Bitcoin Literally FORCE This Crypto To Rocket Up?Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. About Juniper Pharmaceuticals Stock (NASDAQ:JNP)Juniper Pharmaceuticals, Inc., a diversified healthcare company, focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in women's health. It operates in two segments, Product and Service. The company develops its products utilizing its proprietary drug delivery technologies, which include bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa to achieve sustained and controlled delivery of active drug product; and a novel intravaginal ring technology. Juniper Pharmaceuticals, Inc. markets Crinone, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency. Its product candidates include JNP-0101, which is designed to deliver oxybutynin for the treatment of overactive bladder in women; JNP-0201, which contains natural progesterone and estradiol to be used for hormone replacement therapy in menopausal women; and JNP-0301, a natural progesterone for the prevention of preterm birth in women with a short cervical length. The company offers pharmaceutical product development; clinical trial manufacturing; and analytical and consulting services. Juniper Pharmaceuticals, Inc. has collaboration agreements with Merck KGaA and Allergan, as well as patent license agreement with Massachusetts General Hospital. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.Read More Ad Paradigm PressCould Bitcoin Literally FORCE This Crypto To Rocket Up?Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. JNP Stock News HeadlinesJanuary 30, 2024 | msn.comJuniper Networks revenue misses estimates on weak client spendingJanuary 9, 2024 | msn.comWhy Juniper Networks Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving PremarketApril 18, 2024 | Paradigm Press (Ad)Could Bitcoin Literally FORCE This Crypto To Rocket Up?Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…November 24, 2023 | benzinga.comJuniper Networks Stock (NYSE:JNPR), Analyst Ratings, Price Targets, PredictionsOctober 20, 2022 | marketwatch.comJuniper Essential Oil Market : Reliable Business Data Analysis and Forecast by 2028 with Top Countries DataOctober 27, 2021 | finance.yahoo.comZafgen (ZFGN) Presents Favorable New Data on BeloranibSee More Headlines Receive JNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Juniper Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2018Today4/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:JNP CUSIPN/A CIK821995 Webwww.juniperpharma.com Phone617-639-1500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMs. Alicia Secor (Age 55)Pres, CEO & Director Mr. Jeffrey E. Young (Age 45)CFO, Sr. VP of Fin., Treasurer & Sec. Dr. Nikin Patel (Age 45)COO & Director Dr. Shen Luk BScPh.D., Chief Scientific OfficerDr. Claire Madden-Smith BScPh.D., Sr. VP of Juniper Pharma ServicesKey CompetitorsAraviveNASDAQ:ARAVContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZView All Competitors JNP Stock Analysis - Frequently Asked Questions How were Juniper Pharmaceuticals' earnings last quarter? Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) released its quarterly earnings data on Thursday, August, 9th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by $0.18. The specialty pharmaceutical company had revenue of $15.31 million for the quarter, compared to analysts' expectations of $16.30 million. What other stocks do shareholders of Juniper Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Juniper Pharmaceuticals investors own include Novavax (NVAX), Idera Pharmaceuticals (IDRA), Madrigal Pharmaceuticals (MDGL), Synergy Pharmaceuticals (SGYP), Verastem (VSTM), CRISPR Therapeutics (CRSP), Evoke Pharma (EVOK), Exelixis (EXEL), Amicus Therapeutics (FOLD) and Galectin Therapeutics (GALT). This page (NASDAQ:JNP) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsBiden out June 13; Kamala won’t replace him?Paradigm PressOptions trading has suddenly become more reliable.Eagle PublishingTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts1970’s computer coder issues shocking A.I. warningTradeSmithA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Juniper Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.